TSX runs higher on rate cut expectations
DUBLIN - Investment firm Citadel Group has disclosed a 1.53% interest in Mural Oncology plc, according to a regulatory filing published Wednesday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 265,285 shares representing 1.53% of Mural Oncology’s common stock as of August 26, 2025. This includes 237,285 shares owned or controlled directly and 28,000 shares through stock-settled derivatives.
The filing also reveals Citadel maintains short positions equivalent to 1.24% of Mural’s shares, primarily through stock-settled derivatives including options.
Transaction details show Citadel executed multiple trades on August 26, purchasing a total of 14,613 shares at prices ranging from $2.06 to $2.07 per share. The firm also sold 29,553 shares on the same day at prices between $2.06 and $2.07.
The disclosure includes options positions with various strike prices and expiration dates extending to January 2027, with the majority having strike prices of $2.50 and $5.00.
Mural Oncology, an Irish-based biopharmaceutical company, trades under the ISIN code IE000LK2BOB4. The stock has a par value of $0.01 per ordinary share.
The information was provided in a Form 8.3 filing, which is required when an entity holds interests in relevant securities representing 1% or more during an offer period under Irish takeover regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.